Roflumilast Foam

Drug identity checked against registry records

Also recorded as ARQ-154

A drug appearing in a clinical trial does not mean it is FDA-approved. Check the original regulatory source for any approval claim.

Included trials

TrialSponsorPhaseStatusPrimary completion
Trial of PDE4 Inhibition With Roflumilast (ARQ-154) Foam 0.3% for the Management of Seborrheic Dermatitis (STRATUM)NCT04973228ARQTPhase 3Completed2022-04-06Actual

Regulatory dates and decisions

No regulatory events match this view.This does not mean no FDA events have occurred.